Literature DB >> 9540157

Receptors and ligands that mediate activation-induced death of T cells.

M R Alderson1, D H Lynch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9540157     DOI： 10.1007/bf00787226

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  74 in total

1.  Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.

Authors:  T Suda; T Takahashi; P Golstein; S Nagata
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

2.  Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen.

Authors:  M T Abreu-Martin; A Vidrich; D H Lynch; S R Targan
Journal:  J Immunol       Date:  1995-11-01       Impact factor: 5.422

Review 3.  Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.

Authors:  P R Walker; P Saas; P Y Dietrich
Journal:  J Immunol       Date:  1997-05-15       Impact factor: 5.422

4.  Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction.

Authors:  S M Kang; D B Schneider; Z Lin; D Hanahan; D A Dichek; P G Stock; S Baekkeskov
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

Review 5.  The biology of cachectin/TNF--a primary mediator of the host response.

Authors:  B Beutler; A Cerami
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

6.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.

Authors:  S T Ju; D J Panka; H Cui; R Ettinger; M el-Khatib; D H Sherr; B Z Stanger; A Marshak-Rothstein
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

7.  Induction of apoptosis in mature T cells by tumour necrosis factor.

Authors:  L Zheng; G Fisher; R E Miller; J Peschon; D H Lynch; M J Lenardo
Journal:  Nature       Date:  1995-09-28       Impact factor: 49.962

8.  Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.

Authors:  P R Galle; W J Hofmann; H Walczak; H Schaller; G Otto; W Stremmel; P H Krammer; L Runkel
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

9.  Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis.

Authors:  N K Banda; J Bernier; D K Kurahara; R Kurrle; N Haigwood; R P Sekaly; T H Finkel
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

10.  Metalloproteinase-mediated release of human Fas ligand.

Authors:  N Kayagaki; A Kawasaki; T Ebata; H Ohmoto; S Ikeda; S Inoue; K Yoshino; K Okumura; H Yagita
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307
View more
  5 in total

Review 1.  Killer B lymphocytes: the evidence and the potential.

Authors:  Steven K Lundy
Journal:  Inflamm Res       Date:  2009-03-05       Impact factor: 4.575

Review 2.  The future of interleukin-2: enhancing therapeutic anticancer vaccines.

Authors:  W W Overwijk; M R Theoret; N P Restifo
Journal:  Cancer J Sci Am       Date:  2000-02

Review 3.  Regulatory B cells in autoimmune diseases.

Authors:  Min Yang; Ke Rui; Shengjun Wang; Liwei Lu
Journal:  Cell Mol Immunol       Date:  2013-01-07       Impact factor: 11.530

Review 4.  Silica exposure and altered regulation of autoimmunity.

Authors:  Suni Lee; Hidenori Matsuzaki; Naoko Kumagai-Takei; Kei Yoshitome; Megumi Maeda; Ying Chen; Masayasu Kusaka; Kozo Urakami; Hiroaki Hayashi; Wataru Fujimoto; Yasumitsu Nishimura; Takemi Otsuki
Journal:  Environ Health Prev Med       Date:  2014-08-19       Impact factor: 3.674

5.  CD8(+) T cell-mediated injury in vivo progresses in the absence of effector T cells.

Authors:  B A Small; S A Dressel; C W Lawrence; D R Drake; M H Stoler; R I Enelow; T J Braciale
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.